Discover and read the best of Twitter Threads about #asco19

Most recents (6)

Here is a summary of the @ASCO Minimal Common Oncology Data Elements (#mCODE) project ... in thread format
#ASCO19
1/ Problem:
#clinicaltrials continue to be the primary way to answer question in oncology but few patients enroll. Despite more data being stored in the #EHR, we can't easily combine data across systems as few are interoperable. This is a missed opportunity.
2/ Solution:
#mCODE is a newly proposed data standard that leverages and expands existing data standards to promote answering clinically meaningful oncology questions across medical records allowing us to learn from more patients
Read 8 tweets
My only #ASCO19 Tweets will be in this thread. I will post a few abstracts of negative trials with and without positive spin. Things not to do as of June 2019.
This is somewhat obvious, but in case you didn't know, do not give rituximab maintenance for DLBCL. meetinglibrary.asco.org/record/174772/…
Despite these deceptive conclusions, do not use pembrolizumab in
HCC in the second-line setting. meetinglibrary.asco.org/record/173190/…
Read 15 tweets
Landed in Chicago.

Opened email to find yet ANOTHER rejection.

Went to @artinstitutechi to cheer myself up before evening meetings at #asco19.

My manuscript is no masterpiece. But I started thinking: what if our greatest artists had faced the fearsome Reviewer #2?

THREAD/
"If I wanted swirls, I'd order gelato.
Thank u, next"
"In art, we have something called proper perspective.
Look into it."
Read 10 tweets
Here are my Top 5 #ASCO19 @ASCO myeloma abstracts. #ASCO19VR

I’ve listed them with links to the full abstract. @mtmdphd @myelomaMD @MyelomaTeacher @MayoMyeloma @NorthTxMSG @Mohty_EBMT @BldCancerDoc @DrAnasYounes @DrMiguelPerales @JohnPLeonardMD
See thread for countdown! 👇
#5 Isatuximab-Pom-Dex vs Pom-Dex in relapsed refractory myeloma. First phase III with this drug. May lead to FDA approval and provide alternative to Dara (?compete on cost) @DanaFarber @sanofi @mtmdphd @grpetersen1 #ASCO19 #ASCO19VR
abstracts.asco.org/239/AbstView_2…
#4 IMWG Risk stratification for Smoldering Myeloma. ~2000 patient study defines intermediate & high risk smoldering myeloma with simple parameters. Of importance: identifies candidates for early therapy. @mvmateos @myelomaMD @IMFmyeloma #ASCO19 #ASCO19VR
abstracts.asco.org/239/AbstView_2…
Read 8 tweets
[THREAD] Cancer Ontologies and Healthcare Hashtags [Updated: May 24, 2019] (missing 2019 In Press manuscript from @subatomicdoc)
cc: #ASCO19 @chanyoonchea + #HLHsm
Healthcare Hashtag Project - via @symplur @healthhashtags
symplur.com/healthcare-has…
Ontologies @symplur @healthhashtags - CTO, OTO, HTO, Cardiology, Pathology, Radiology, Urology ow.ly/ll4530csaDm
Read 13 tweets
Excellent overview of the cell therapy landscape from Piper Jaffray

$GILD $NVS $CELG $JNJ $AMGN $ALLO $BLUE $IOVA $AUTL $SGMO $ATRA $CRSP $FATE $CLLS $NTLA $DTIL $ZIOP $MRKR $CYAD $BLCM $TCRR $ADAP $MBIO $NTGN $UMRX $MXCT $GMDA $SRNE $KDS $MDGEF $NK $ANIX $KITE $JUNO #ASGCT19
New article from @NatRevDrugDisc looks at the global #CellTherapy landscape: nature.com/articles/d4157…

Now, the global cell therapy pipeline includes 1,011 active agents, 258 more than a year ago.

#ASCO19
@NatRevDrugDisc Guggenheim highlights next-generation #CellTherapy approaches

1st gen: $ADAP $AMGN $ATRA $AUTL $BLCM $BLUE $CELG $CBMG $CYAD $FBIO $GILD $GSK $XON $IOVA $JNJ $MXCT $MDGEF $NVS $SRNE $TCRR $ZIOP

Next-gen: $ALLO $ATRA $CLLS $DTIL CYAD $BLCM $EVTCY $FATE $EDIT $RUBY $ERYP

#ASCO19
Read 4 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!